美国 - 英文 - NLM (National Library of Medicine)

hy-vee - hydrogen peroxide (unii: bbx060an9v) (hydrogen peroxide - unii:bbx060an9v) - hydrogen peroxide 2.65 ml in 100 ml - first aid antiseptic/oral debriding agent - first aid to help prevent the risk of infection in minor cuts, scrapes and burns - aids in the removal of phlegm, mucus, or other secretions associated with occasional sore mouth

澳大利亚 - 英文 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

hy-clor (australia) pty ltd - chlorine present as trichloroisocyanuric acid; copper present as copper sulfate pentahydrate - tablet (inc. pellet, bolus, suppository, capsule) - chlorine present as trichloroisocyanuric acid mineral-chlorine-acid active 800.0 g/kg; copper present as copper sulfate pentahydrate mineral-copper active 30.0 g/kg - pool chlorine - swimming pool - outdoor - algae | bacteria

加拿大 - 英文 - Health Canada

dechra ltd - hyaluronate sodium - solution - 17mg - hyaluronate sodium 17mg - horses

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

hy clor pty ltd -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

hy clor pty ltd -

欧盟 - 英文 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - daptomycin - gram-positive bacterial infections; bacteremia; soft tissue infections; endocarditis, bacterial - antibacterials for systemic use, - cubicin is indicated for the treatment of the following infections.adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cssti).adult patients with right-sided infective endocarditis (rie) due to staphylococcus aureus.it is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.adult and paediatric (1 to 17 years of age) patients with staphylococcus aureus bacteraemia (sab). in adults, use in bacteraemia should be associated with rie or with cssti, while in paediatric patients, use in bacteraemia should be associated with cssti.daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, cubicin should be co-administered with appropriate antibacterial agent(s). consideration should be given to official guidance on the appropriate use of antibacterial agents.

欧盟 - 英文 - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. 

美国 - 英文 - NLM (National Library of Medicine)

smiths medical asd, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine spinal is indicated for the production of subarachnoid block (spinal anesthesia). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of spinal anesthesia. marcaine spinal is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type. the following conditions preclude the use of spinal anesthesia: 1. severe hemorrhage, severe hy

美国 - 英文 - NLM (National Library of Medicine)

smiths medical asd, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine spinal is indicated for the production of subarachnoid block (spinal anesthesia). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of spinal anesthesia. marcaine spinal is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type. the following conditions preclude the use of spinal anesthesia: 1. severe hemorrhage, severe hy

美国 - 英文 - NLM (National Library of Medicine)

viatrexx bio incorporated - sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), bos taurus adrenal gland (unii: m2776swb29) (bos taurus adrenal gland - unii:m2776swb29), pork collagen (unii: i8442u2g7j) (pork collagen - unii:i8442u2g7j), cuminaldehyde (unii: o0893nc35f) (cuminaldehyde - unii:o0893nc35f), dioscorea villosa tuber (unii: iwy3iwx2g8) (dioscorea villosa tuber - unii:iwy3iwx2g8), sus scrofa red blood cell (unii: 5x23igf970) (sus scrofa red blood cell - unii:5x23igf970), bos taurus red b - viatrexx-facial a sterile, injectable, biodegradable, clear isotonic liquid that is injected into the various layers of the skin, muscles, ligaments, joints, other body tissues or added to an iv, either as a push or into the bag. this product should not be used in patients with a known hypersensitivity to any ingredient found in the formula, porcine products, isotonic saline or benzyl alcohol, or patients with a history of severe allergies. as with all injections, epinephrine injection (1:1,000) must be immediately available should an acute anaphylactoid reaction occur due to any component of the injection. this product contains 1% benzyl alcohol. benzyl alcohol has been reported to be associated with a fatal "gasping syndrome" in premature infants. due to the benzyl alcohol content, this product should not be given to a pregnant woman. this product should not be used in patients with a known hypersensitivity to any ingredient in this formula, porcine products, isotonic saline or benzyl alcohol, or patients